StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ELLOBullishEarningsnews
High materiality9/10

Ellomay's H1 2026 results benefit from Luzon sale; liquidity improves

Aug 18, 2026, 4:14 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

One-off Luzon sale catalyzes large net profit from discontinued operations and tax benefits, boosting reported earnings and cash on hand. The balance sheet shows solid liquidity (€113.5m cash) and manageable net debt (€50.9m), with a compelling EBITDA base (€90.6m for H1). Execution of US/Italy/NL projects and favorable regulatory edges (FER X, storage expansion) support valuation upside, at least in the near term. FX headwinds remain a risk, but net debt to EBITDA remains favorable.

AI summary

What happened, with direct paths to the underlying reporting

Ellomay Capital reported unaudited H1 2026 results, with €21.1m six-month revenue and €58.3m net income, driven largely by a €94.8m capital gain from selling Ellomay Luzon Energy; results include discontinued operations. Cash rose to €113.5m and net debt stood at €50.9m, underpinning liquidity for an expansive project pipeline in Italy, the US and the Netherlands. EBITDA reached €90.6m for six months, underscoring a strong operating base despite FX headwinds and ongoing capital needs.

  • Ellomay reports H1 2026 results; Luzon sale yields €94.8m net capital gain.
  • Six-month revenue €21.1m; EBITDA €90.6m; net income €58.3m; discontinued ops boost.
  • Cash €113.5m; net debt €50.9m; liquidity supports pipeline expansion.
  • Italy/USA/Netherlands project updates; FER X tenders; Hillsboro (14 MW) grid in Sept 2026.
  • FX: NIS strength against euro raises financing costs; net FX-adjusted financing ≈€2.3m.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.